register

News & Trends - Biotechnology

Biotech start-up to boost microbiome drug development in Asia Pacific

Health Industry Hub | February 12, 2021 |
[Total: 1    Average: 5/5]

Biotech News: Executive Thomas Mitchell is set to drive growth, innovation and expansion across Asia Pacific for thriving biotechnology start-up BiomeBank, Australia’s first public stool bank and microbiome therapeutics company, bringing with him a wealth of experience in the discovery and development of microbiome drug products.

Relocating to South Australia from Cambridge UK, Mr Mitchell takes the reins as CEO of BiomeBank to enable effective translation of the company’s portfolio of assets.

The company is soon expected to gain TGA approval of their GMP facility which manufactures a broad-spectrum live biotherapeutic product (LBP) for prevention of recurrent Clostridioides difficile with plans to expand it to other indications.

Established in 2016 by co-founders and Adelaide-based gastroenterologists Dr Sam Costello and Dr Robert Bryant, BiomeBank opened its purpose-built laboratory in Thebarton in March 2020 to enable the quality-controlled donation of healthy stool from donors, to provide safe access to faecal microbiota transplant (FMT) material. This next stage will see the company develop multiple microbiome drug products, establishing itself as the leading microbiome company in the APAC region.

FMT has been shown to be a safe and effective treatment in the prevention of recurrent Clostridioides difficile (C-diff), with emerging evidence demonstrating the microbiome has the ability to treat other diseases such as ulcerative colitis where Dr Costello and Dr Bryant have demonstrated efficacy in a landmark trial published in JAMA.

You may also like Ex-Pfizer Julie Liu joins biotech Cerecin as new Vice President of R&D

BiomeBank has provisional approval for use and supply of FMT, as a class 2 biologic, in Australia and is planning a submission to the TGA in 2021 for specific indications.

BiomeBank Chair Dr Stephen Rodda said the new CEO appointment represents a significant milestone in the growth and success of the developing biotech company as they look to deliver more impact for patients with debilitating gut diseases across the Asia Pacific region.

“Thomas brings strong expertise in microbiome drug development, having occupied previous leadership positions at both Finch Therapeutics and Microbiotica, key microbiome biotech companies in Boston USA and Cambridge UK,” Dr Rodda said.

“This is an exciting period for BiomeBank as we head towards TGA approval for our product, which will be used to treat unmet medical need in many indications across Australia with the potential for global expansion.”

South Australia’s Chief Scientist Professor Caroline McMillen also applauded the new CEO appointment and the innovation mindset of the BiomeBank team. 

“I was thrilled to hear Thomas Mitchell accepted this position and was relocating to Adelaide, which is emerging as a magnet city, attracting talent from across the globe,” Prof McMillen said.

“I’m very much looking forward to the many innovations for gut health that will be made possible through BiomeBank with a passionate expert team at the helm.”

Mr Mitchell will be backed by the expertise of Chief Medical Officer Dr Sam Costello and Chief Technology Officer Dr Sam Forster, both of which have made important contributions to the microbiome field.

BiomeBank’s new CEO Mr Mitchell expressed his excitement stating the conditions are right for BiomeBank to make a meaningful impact on the global stage.  

“It is an exciting opportunity to return to Australia and join a world-class team of microbiome experts to develop microbiome therapeutics. With BiomeBank’s talent and pipeline we are well-positioned to be a leader in the field,” he concluded.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Leadership & Management

Leadership Management Qualities - The power of being an authentic leader

The power of being an authentic leader

Health Industry Hub | April 21, 2021 |

Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Data is the biggest challenge, and opportunity, for MedTech

Data is the biggest challenge, and opportunity, for MedTech

Health Industry Hub | April 21, 2021 |

Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]

More


News & Trends - Medical Technology

MedTech News - Thermo Fisher acquisition to better serve its pharma and biotech clients

Thermo Fisher acquisition to better serve its pharma and biotech clients

Health Industry Hub | April 21, 2021 |

MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]

More


News & Trends - Pharmaceuticals

Pharma News - First-in-class oncology drug candidate licensed by Aussie pharma

First-in-class oncology drug candidate licensed by Aussie pharma

Health Industry Hub | April 21, 2021 |

Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]

More